Pharmaceutical USA-based ArQule and Japanese drug major Daiichi Sankyo say they will move forward with a Phase III clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the US Food and Drug Administration for a trial comparing ARQ 197 plus erlotinib against erlotinib plus placebo. 4 August 2010